Skip to main content

CORRECTION article

Front. Pharmacol., 05 January 2023
Sec. Obstetric and Pediatric Pharmacology
Volume 13 - 2022 | https://doi.org/10.3389/fphar.2022.1116575

Corrigendum: Improving therapy of pharmacoresistant epilepsies: The role of fenfluramine

This article is a correction to:

  1. Improving Therapy of Pharmacoresistant Epilepsies: The Role of Fenfluramine

    1. Read original article
Gianluca Dini Gianluca Dini1*Eleonora TulliEleonora Tulli1Giovanni Battista Dell&#x;IsolaGiovanni Battista Dell’Isola1Elisabetta MencaroniElisabetta Mencaroni1Giuseppe Di CaraGiuseppe Di Cara1Pasquale Striano,Pasquale Striano2,3Alberto VerrottiAlberto Verrotti1
  • 1Department of Pediatrics, University of Perugia, Perugia, Italy
  • 2Pediatric Neurology and Muscular Diseases Unit, IRCCS “G. Gaslini” Institute, Genoa, Italy
  • 3Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Genoa, Italy

A Corrigendum on
Improving therapy of pharmacoresistant epilepsies: The role of fenfluramine

by Dini G, Tulli E, Dell’Isola GB, Mencaroni E, Di Cara G, Striano P and Verrotti A (2022). Front. Pharmacol. 13:832929. doi: 10.3389/fphar.2022.832929

In the published article, there was an error. The conclusions of the article should be more cautionary and provide a more objective stance on the benefits and risks of this drug and its use. As such, a correction has been made to the Conclusion, final sentence. The original sentence reads as follows: “FFA showed an overall favorable profile of safety and tolerability, with mostly mild side effects, pointing out that significant benefits outweigh potential cardiac risks.”

The corrected sentence appears below: “FFA showed an overall favorable profile of safety and tolerability, with mostly mild side effects, suggesting that benefits might outweigh potential cardiac risks, although this will need to be established in targeted investigations.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: fenfluramine, pharmacoresistant epilepsy, Dravet syndrome, Lennox-Gastaut syndrome, anti-seizure medication (ASM)

Citation: Dini G, Tulli E, Dell’Isola GB, Mencaroni E, Di Cara G, Striano P and Verrotti A (2023) Corrigendum: Improving therapy of pharmacoresistant epilepsies: The role of fenfluramine. Front. Pharmacol. 13:1116575. doi: 10.3389/fphar.2022.1116575

Received: 05 December 2022; Accepted: 21 December 2022;
Published: 05 January 2023.

Edited and reviewed by:

Annalisa Capuano, University of Campania Luigi Vanvitelli, Italy

Copyright © 2023 Dini, Tulli, Dell’Isola, Mencaroni, Di Cara, Striano and Verrotti. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Gianluca Dini, gianlucadini90@gmail.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.